Dr. William M. Lee, MD
Hepatology (Hepatology Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in Texas since 1991, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hepatology Physician primary
TX license H9452 (first issued 1991; texas retired - emeritus)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 3 companies reported 9 payments worth $10,532 in total to this clinician.
| GlaxoSmithKline, LLC. | $7,200 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $3,225 |
| Novo Nordisk Inc | $107 |
| Consulting Fee | $10,425 |
|---|---|
| Food and Beverage | $107 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Nov 4, 2025 | Consulting Fee | $3,225 |
| GlaxoSmithKline, LLC. Apr 15, 2025 | Consulting Fee | $2,800 |
| GlaxoSmithKline, LLC. Oct 28, 2025 | Consulting Fee | $1,800 |
| GlaxoSmithKline, LLC. Dec 5, 2025 | Consulting Fee | $1,400 |
| GlaxoSmithKline, LLC. Jul 23, 2025 | Consulting Fee | $1,200 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $64,618 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132)
Bausch Health US, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.